Drug Repurposing

While gene therapy offers the possibility of addressing the underlying cause of FARS2 deficiency, existing medications and compounds may provide a faster path to helping people living with the disease.

Drug repurposing involves identifying medications already approved or studied for other conditions that might also benefit people with FARS2 deficiency.

This approach has several advantages. Because many of these compounds have already undergone safety testing in humans, researchers may be able to evaluate their potential for FARS2 more quickly and at lower cost than developing entirely new drugs.

Our goal is to identify treatments that could improve cellular function, reduce symptoms, or slow disease progression while longer-term therapies are being developed.

Our Research Strategy

We're working with researchers and medical institutions to investigate compounds that may help cells affected by FARS2 deficiency function more effectively.

Our approach combines several lines of investigation:

  • Screening existing compounds. Researchers use laboratory models of FARS2 deficiency to test whether approved medications and other compounds can improve cellular function.

  • Testing promising candidates in patient cells. Compounds that show encouraging results can be evaluated in cells from people with FARS2 deficiency to determine whether their effects are reproducible.

  • Studying mitochondrial function. Researchers are investigating therapies that may improve energy production, reduce cellular stress, or compensate for the effects of defective FARS2 proteins.

  • Evaluating combinations. Some treatments may work better together than individually, creating opportunities for combination therapies.

  • Moving promising candidates toward clinical use. When sufficient evidence exists, researchers and physicians can evaluate whether a medication warrants carefully supervised clinical testing.

What We've Learned So Far

FARS2 drug repurposing research has already produced encouraging findings.

Previous laboratory studies have screened thousands of compounds, identifying several candidates worthy of further investigation.

One particularly interesting approach involves L-phenylalanine, an amino acid used by the FARS2 enzyme.

In a small published study involving a child with FARS2 deficiency, phenylalanine supplementation was associated with improvements in motor function. Additional laboratory studies have provided evidence supporting further investigation of this approach.

These findings are encouraging but preliminary. They do not establish that phenylalanine is an effective treatment for all people with FARS2 deficiency, and any use requires appropriate medical supervision.

Other compounds have shown promising effects in laboratory models, although additional research is needed to establish their effectiveness and safety.

Our Research Partners

Our drug repurposing strategy draws on work by several research groups, including:

  • Children's Hospital of Philadelphia (CHOP): Researchers are using laboratory models to investigate potential treatments for FARS2 and related mitochondrial disorders.

  • UCLA and Perlara: Previous screening efforts identified compounds that may improve cellular function in FARS2 deficiency.

  • Children's Hospital Colorado: Researchers have investigated approaches to improving mitochondrial function.

  • Stanford University: Clinical research offers opportunities to evaluate potential therapies for mitochondrial diseases.

We're working to bring together findings from these different efforts, identify the most promising candidates, and avoid unnecessary duplication of research.

The Path Forward

Our immediate priority is to turn promising laboratory findings into a focused treatment-development strategy.

That means:

  1. Comparing results from different research programs.

  2. Identifying the strongest candidates for additional testing.

  3. Validating promising compounds in relevant disease models.

  4. Assessing safety, accessibility, and the potential for clinical evaluation.

  5. Working with clinicians to determine whether selected treatments merit formal studies in patients.

Drug repurposing may not provide a cure. But even a treatment that slows disease progression or preserves mobility could significantly improve patients' lives.

Helping Other Rare Disease Patients

The potential benefits extend beyond FARS2.

Many rare genetic conditions affect mitochondrial function and share biological pathways. Research into treatments for FARS2 may generate knowledge and tools that help scientists identify therapies for related disorders.

Our goal is to find treatments that can make a difference as soon as possible—and help create a faster, more affordable pathway to therapies for other rare diseases.